[HTML][HTML] Properties and functions of fibroblasts and myofibroblasts in myocardial infarction
The adult mammalian heart contains abundant interstitial and perivascular fibroblasts that
expand following injury and play a reparative role but also contribute to maladaptive fibrotic …
expand following injury and play a reparative role but also contribute to maladaptive fibrotic …
[HTML][HTML] Slowing the progression of diabetic kidney disease
O Blazek, GL Bakris - Cells, 2023 - mdpi.com
Diabetes is the most frequent cause of kidney disease that progresses to end-stage renal
disease worldwide, and diabetic kidney disease is significantly related to unfavorable …
disease worldwide, and diabetic kidney disease is significantly related to unfavorable …
[HTML][HTML] Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease
DL Kim, SE Lee, NH Kim - Endocrinology and Metabolism, 2023 - synapse.koreamed.org
Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in
patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular …
patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular …
[HTML][HTML] Nonsteroidal Mineralocorticoid receptor antagonism by finerenone—translational aspects and clinical perspectives across multiple organ systems
P Kolkhof, R Lawatscheck, G Filippatos… - International journal of …, 2022 - mdpi.com
Perception of the role of the aldosterone/mineralocorticoid receptor (MR) ensemble has
been extended from a previously renal epithelial-centered focus on sodium and volume …
been extended from a previously renal epithelial-centered focus on sodium and volume …
[HTML][HTML] Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
R Lv, L Xu, L Che, S Liu, Y Wang, B Dong - Frontiers in endocrinology, 2023 - frontiersin.org
Chronic kidney diseases (CKD) and cardiovascular diseases (CVD) are the main
complications in type 2 diabetic mellitus (T2DM), increasing the risk of cardiovascular and all …
complications in type 2 diabetic mellitus (T2DM), increasing the risk of cardiovascular and all …
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
RA DeFronzo, GL Bakris - Diabetes, Obesity and Metabolism, 2022 - Wiley Online Library
In patients with type 2 diabetes, chronic kidney disease (CKD) is the most common cause of
kidney failure. With its increasing prevalence and limited treatment options, CKD is a major …
kidney failure. With its increasing prevalence and limited treatment options, CKD is a major …
[HTML][HTML] Mineralocorticoid receptor activation in vascular insulin resistance and dysfunction
AE Igbekele, G Jia, MA Hill, JR Sowers… - International Journal of …, 2022 - mdpi.com
Systemic insulin resistance is characterized by reduced insulin metabolic signaling and
glucose intolerance. Mineralocorticoid receptors (MRs), the principal receptors for the …
glucose intolerance. Mineralocorticoid receptors (MRs), the principal receptors for the …
[HTML][HTML] XBP1 modulates the aging cardiorenal system by regulating oxidative stress
J Zhang, Y Zhao, N Gong - Antioxidants, 2023 - mdpi.com
X-box binding protein 1 (XBP1) is a unique basic-region leucine zipper (bZIP) transcription
factor. Over recent years, the powerful biological functions of XBP1 in oxidative stress have …
factor. Over recent years, the powerful biological functions of XBP1 in oxidative stress have …
The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances
X Chen, X Li, K Zhang, K Lian, W Zhang… - Clinical and …, 2024 - Springer
Background Chronic kidney disease (CKD) poses a significant health risk in contemporary
society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system …
society. Current CKD treatments primarily involve renin-angiotensin-aldosterone system …
[HTML][HTML] Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
A Mazzieri, F Porcellati, F Timio, G Reboldi - International Journal of …, 2024 - mdpi.com
Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …
diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) …